Self-Immolative Carbamate Linkers for CD19-Budesonide Antibody-Drug Conjugates

08 August 2023, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Antibody-drug conjugates consist of potent small molecule payloads linked to a targeting antibody. Payloads must possess a viable functional group by which a linker for conjugation can be attached. Linker-attachment options remain limited for connection to payloads via hydroxyl groups. A releasing group based on 2-aminopyridine was developed to enable stable attachment of para-aminobenzyl carbamate (PABC) linkers to the C21-hydroxyl group of budesonide, a glucocorticoid receptor agonist. Payload release involves a cascade of two self-immolative events that are initiated by protease-mediated cleavage of the dipeptide-PABC bond. Budesonide release rates were determined for a series of payload-linker intermediates in buffered solution at pH 7.4 and pH 5.4, leading to the identification of 2-aminopyridine as the preferred releasing group. Addition of a polyethylene glycol group improved linker hydrophilicity, thereby providing CD19-budesonide ADCs with suitable properties. ADC23 demonstrated targeted budesonide delivery to CD19 expressing cells and inhibited B-cell activation in mice.

Keywords

Antibody-drug conjugate
budesonide
glucocorticoid receptor modulator
steroid
protease cleavable linker
self-immolative
CD19
targeted drug delivery

Supplementary materials

Title
Description
Actions
Title
Supporting Information CD19-Budesonide ADCs
Description
Synthetic procedures and characterization data for intermediate compounds and ADCs. ADC stability data in buffer and mouse plasma.
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.